- Home
- VIGL vs RRGB Comparison
VIGL vs RRGB Comparison
Compare VIGL & RRGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- RRGB
- Stock Information
- Founded
- VIGL 2020
- RRGB 1969
- Country
- VIGL United States
- RRGB United States
- Employees
- VIGL N/A
- RRGB N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- RRGB Restaurants
- Sector
- VIGL Health Care
- RRGB Consumer Discretionary
- Exchange
- VIGL Nasdaq
- RRGB Nasdaq
- Market Cap
- VIGL 95.2M
- RRGB 91.6M
- IPO Year
- VIGL 2022
- RRGB 2002
- Fundamental
- Price
- VIGL $2.08
- RRGB $5.72
- Analyst Decision
- VIGL Strong Buy
- RRGB Strong Buy
- Analyst Count
- VIGL 5
- RRGB 3
- Target Price
- VIGL $19.75
- RRGB $12.50
- AVG Volume (30 Days)
- VIGL 331.7K
- RRGB 277.1K
- Earning Date
- VIGL 11-07-2024
- RRGB 02-26-2025
- Dividend Yield
- VIGL N/A
- RRGB N/A
- EPS Growth
- VIGL N/A
- RRGB N/A
- EPS
- VIGL N/A
- RRGB N/A
- Revenue
- VIGL N/A
- RRGB $1,272,359,000.00
- Revenue This Year
- VIGL N/A
- RRGB N/A
- Revenue Next Year
- VIGL N/A
- RRGB $0.95
- P/E Ratio
- VIGL N/A
- RRGB N/A
- Revenue Growth
- VIGL N/A
- RRGB N/A
- 52 Week Low
- VIGL $1.49
- RRGB $2.97
- 52 Week High
- VIGL $6.06
- RRGB $11.15
- Technical
- Relative Strength Index (RSI)
- VIGL 55.12
- RRGB 55.72
- Support Level
- VIGL $1.79
- RRGB $5.31
- Resistance Level
- VIGL $2.02
- RRGB $5.99
- Average True Range (ATR)
- VIGL 0.16
- RRGB 0.37
- MACD
- VIGL 0.08
- RRGB 0.01
- Stochastic Oscillator
- VIGL 96.72
- RRGB 51.33
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue.